Global DNA Repair Drugs Market, by Drug Type (Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), and Talazoparib (Talzenna)), by Application (Ovarian Cancer, and Breast Cancer), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued US$ 461.3 million in 2017, and projected to exhibit CAGR of 32.4% over the forecast period (2018 – 2026), as highlighted in a new report published by . Increasing collaborations and acquisitions, along with new product approvals is expected to augment the market growth.

Key players in the market are focusing on strategic collaborations and acquisitions, to increase their geographical positioning and expand their product portfolio in the global DNA repair drugs market. In July 2017, AstraZeneca and Merck & Co., Inc. announced plans to collaborate over the development and commercializing of AstraZeneca’s LYNPARZA (olaparib) indicated in treatment of multiple cancer types. In January 2018, AstraZeneca Plc. received an approval from the Japanese Ministry of Health, Labor and Welfare for Lynparza (olaparib) tablets used as maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer. Moreover, rising investment and funding by regional governments and other organizations is expected to boost the market growth. In February 2019, the Liberal National Government of Australia announced an investment of US$ 1.14 Mn for an innovative pilot project supporting women with ovarian cancer. The government included Lynparza in its 'Pharmaceutical Benefits Scheme' which can save medicine expenses of patients up to US$ 64,400 a year.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/dna-repair-drugs-market-2617

Browse 31 Market Data Tables and 24 Figures spread through 206 Pages and in-depth TOC on ‘DNA Repair Drugs Market’- Global Forecast to 2026, by Drug Type (Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), and Talazoparib (Talzenna)), by Application (Ovarian Cancer, and Breast Cancer), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Furthermore, increasing incidence of cancer, is expected to drive the market growth. According to the World Cancer Research Fund International’s report in 2018, breast cancer accounted for second highest number of cancer cases among all the cancer cases worldwide, accounting 2,088,849 new cases across the globe in 2018. Key players are focused on partnerships and acquisitions in order to expand their product portfolio in the global DNA repair drugs market. In May 2019, Clovis Oncology, Inc., in collaboration with Bristol-Myers Squibb Company and Foundation Medicine Inc., initiated Phase II trials to evaluate efficacy of Rucaparib in combination with Nivolumab in patients with high-grade serous carcinoma (HGSC) or endometrioid ovarian cancer. In January 2019, GlaxoSmithKline plc. a U.K.-based company, acquired TESARO, Inc. for around US$ 5.1 billion for drug development of Zejula in multiple cancer treatments.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2617

Key Takeaways of the DNA Repair Drugs Market:

The global DNA repair drugs market is expected to exhibit CAGR of 32.4% over the forecast period, due to increasing incidence of cancer. According to the World Health Organization (WHO), 2012, cancer is the second leading cause of morbidity and mortality worldwide, with 14 million new cases registered in 2012. Furthermore, the WHO stated that the number of new cases is expected to rise by 70% in 2030. In 2015, cancer was responsible for 8.8 million deaths worldwide, accounting 1 out of 6 deaths particularly in low and middle income countries.

Among drug types, the Olaparib (Lynparza) segment dominated the global DNA repair drugs market in 2018, owing to increasing number of product approvals in developed and emerging economies around the globe. For instance, in May 2019, AstraZeneca plc. and Merck received the Health Canada approval for Lynparza as a monotherapy maintenance treatment for patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Among application, the ovarian cancer segment held dominant position in the global DNA repair drugs market in 2018, as DNA repair drugs are largely used for treatment of ovarian cancer.

Among distribution channel, the hospital pharmacies segment held a dominant position in the DNA repair drugs market in 2018, increasing number of retail pharmacies and increasing trend of customer engagement is expected to exhibit high growth over the forecast period.

Key players operating in the global DNA repair drugs market are AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui Medicine Co., Ltd.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2617

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737